Cargando…
A novel role for an old target: CD45 for breast cancer immunotherapy
Breast cancer subtypes have not shown significant response to current immunomodulatory therapies. Although most subtypes are treatable, triple negative breast cancer (TNBC), an aggressive highly metastatic cancer, comprising 10–20% of breast cancers, remains an unmet medical need. New strategies are...
Autores principales: | Raiter, Annat, Zlotnik, Oran, Lipovetsky, Julia, Mugami, Shany, Dar, Shira, Lubin, Ido, Sharon, Eran, Cohen, Cyrille J., Yerushalmi, Rinat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158046/ https://www.ncbi.nlm.nih.gov/pubmed/34104545 http://dx.doi.org/10.1080/2162402X.2021.1929725 |
Ejemplares similares
-
TNBC-derived Gal3BP/Gal3 complex induces immunosuppression through CD45 receptor
por: Raiter, Annat, et al.
Publicado: (2023) -
Chemotherapy Controls Metastasis Through Stimulatory Effects on GRP78 and Its Transcription Factor CREB3L1
por: Raiter, Annat, et al.
Publicado: (2020) -
Downregulation of CD45 Signaling in COVID-19 Patients Is Reversed by C24D, a Novel CD45 Targeting Peptide
por: Alon, Danny, et al.
Publicado: (2021) -
GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment
por: Raiter, Annat, et al.
Publicado: (2020) -
Pharmacological induction of cell surface GRP78 contributes to apoptosis in triple negative breast cancer cells
por: Raiter, Annat, et al.
Publicado: (2014)